Partnerships to Advance Cancer Health Equity (PACHE) Program Meeting

Program updates

H. Nelson Aguila, D.V.M., CRCHD, NCI September 8, 2023

CENTER TO REDUCE CANCER HEALTH DISPARITIES




NCI Center to Reduce Cancer Health Disparities

Diversity Training





Workforce Diversity





Networks

- Connecting
 Underrepresented
 Populations to
 Clinical Trials
 (CUSP2CT)
- Transformative
 Educational
 Advancement and
 Mentoring Network
 (TEAM)

Partnerships

Partnerships to Advance Cancer Health Equity (PACHE)

Disparities and Equity Program

- Basic research
- Translational research
- Behavioral research
- DEIA



PACHE P20 Program Updates

PAR-22-239: Feasibility Studies to Build Collaborative Partnership in Cancer Research

- Launched in 2001
- Reissued ten times- latest in 2022
- 322 new applications received (161 Partnerships), and 104 awards issued (52 partnerships)
- Supported 300 Pilot Research Projects
- Trained > 274 Junior Investigators
- Current grant portfolio is 12 awards (6 Partnerships, including 2 in a no-cost-extension)
- PAR-22-239 expired on January 7, 2023. This NOFO will not be reissued!

PAR-22-249: Comprehensive Partnerships to Advance Cancer Health Equity, C-PACHE (U54)

- PAR-22-249 expired on January 7, 2023.
 - Under development for publication in FY 24; review and awards
- External evaluation of the U54 CPACHE from 2014 to 2021
 - Completed in 2022
- Current U54 grant portfolio is 36 awards
 - (16 partnerships, including one new U54, one in bridge support, and one in a no cost extension)

External Evaluation

- Data collected from 14 U54 Partnerships
 - RPPR
 - Questionnaire distributed to each Partnership by CRCHD
 - Reports from the Partnership to the PSC
- Evaluation Focus:
 - Infrastructure/Functional Characteristics
 - Cancer Research
 - Cancer Training, Career Development, and Education
 - Cancer Outreach
 - Capacity Building
 - Contribution to NCI Strategic Goals

Relevant findings from the external evaluation

- The CPACHE program has:
 - Made sustained contributions to the science of health disparities
 - Provided a valuable pipeline for the career development of underrepresented investigators
 - Supported the development of several senior underrepresented investigators in leadership positions
 - Fostered innovative and impactful science in CCs and ISUPSs
 - Been an important driver of equity and inclusion within the NIH portfolio
 - Afforded access to the ISUPSs to critical physical resources and knowledge resources (collaborations with CC investigators) for cancer research
 - Aligned with NCI's scientific priorities, contributing to the mechanisms, prevention, treatment, detection, and diagnosis and advancing public health of cancer

Relevant recommendations from the external evaluation

- Coordinate with CCSG (P30) on the new Plan to Enhance Diversity (PED)
- Provide credit in the PED for joint appointments to CCs
- Increase access to CC resources from ISUPS investigators
- Develop strategies to protect the time of ISUPS clinicians and scientists
- Build protected time for U54 investigators to participate in community outreach and engagement
- Implement uniform reporting of
 - Outcomes and set metrics
 - Joint publications and funding

Program Recommendations

- Tracking outcomes of trainees, including students, postdoctoral trainees, and Early Stage Investigators
- Tracking the cancer health disparities (CHD) research and determining the increasing CHD research at Cancer Centers
- Evaluate the impact of the program on cancer health disparities research
- Evaluate the impact of the program on community outreach
- Evaluate the impact of the program on education, training, and career development





cancer.gov/crchd